Icagen breathes freely as Phase IIa asthma trial enthuses investors
04 September 2009
Asher Mullard
Please Login to read the full article.
04 September 2009
Asher Mullard
asher.mullard@informa.com
Icagen's potassium channel antagonist, senicapoc, failed to produce statistically significant differences to placebo in a Phase IIa allergic asthma trial, but still sent share prices soaring by almost 50%, to close at $1.43 on Nasdaq on September 1st after data were released. Share prices have since...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Almirall and Forest to expand aclidinium COPD franchise with Phase III combination trials
- Boehringer Ingelheim's IPF drug impresses despite non-significant data
- FDA grants fast-track status for DARA's PhII candidate for chemotherapy-induced neuropathic pain
- With $14M new funding in hand, Pulmatrix takes on COPD, cystic fibrosis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
